Biotech VCs topped tech peers; AMAG Pharmaceuticals rebounds from FDA safety setback;

@FierceBiotech: Amgen widens cancer reach in $1B-plus Micromet deal. Story | Follow @FierceBiotech

> Bruce Booth of Atlas Venture and Highland Capital Partners' Bijan Salehizadeh have a new study that might dispel any myths about life sciences venture capitalist underperforming their tech peers. Blog

> AMAG Pharmaceuticals ($AMAG) took a hit after the FDA slapped safety warnings on its lead drug Feraheme, but the company appears to be making a comeback. Article

> Seeking Alpha has a piece that argues why drug developer Zalicus ($ZLCS) could be takeover bait for large companies like Pfizer ($PFE) and Amgen ($AMGN). Item

> Proteros Biostructures says that it has renewed its pact with Rigel Pharmaceuticals to aid Rigel's drug discovery efforts with its structural biology services. Release

Pharma News

@FiercePharma: Novartis' desire for deals to return soon, CEO says. News | Follow @FiercePharma

> PhRMA: U.S. drug discounts could cost 260K jobs. Report

> Gilead first to jump into AIDS patent pool. Article

> Novartis mulls IPO on China's planned int'l board. Item

> EMA broadens safety review on Sanofi's Multaq. Story

Biotech Research News

> 'Super' stem cell keeps liver cancer going. News

> NCI chief says no retreat from fundamental research. Story

> Sunburn pain discovery could lead to better arthritis treatments. Article

> Hutchinson takes lead on followup to 'Berlin Patient' HIV cure. Report

> Metamark finds proteins that predict melanoma spread. News

> New gonorrhea strain resistant to all available antibiotics. Story

Manufacturing News

> EU may add environmental regs to GMPs. Item

> Lilly: Put law enforcement on the online fakes case. Story

> Tamiflu concentration change aids dosing accuracy. Report

> Chinese chemical inconsistency yields drug 'caveat emptor.' Story

> Oncologist: U.S. may need drug czar to stem shortages. Article

> Make generics look like brand drugs for safety. Item

And Finally... Drug developer Intellikine says that it named former Celgene executive Gregory Berk as its chief medical officer. Release